Illuminating the Road Less Traveled in Biotech: Radiopharmaceuticals

This report examines the evolving role of radiopharmaceuticals and PET imaging in the diagnosis and monitoring of Alzheimer's disease. It highlights the continued clinical importance of PET scans alongside emerging blood-based biomarkers.

Key Takeaways

• 1.The radiopharmaceutical industry, particularly PET imaging, remains a secular growth area in biotech, driven by the diagnostic requirements of new anti-amyloid Alzheimer's therapies.
• 2.While blood-based biomarkers are emerging as screening tools, PET imaging remains essential for definitive diagnosis, monitoring treatment response, and staging Alzheimer's.

Table of Contents

• Introduction
• Background on Alzheimer's Disease
• Alzheimer's Disease Pathology
• Treatment Landscape for Alzheimer's Disease
• Investigational therapies
• The Role of Diagnostics
• Overview of the Alzheimer's Disease Imaging Market
• Amyloid-Beta PET Agents
• Tau PET Agents
• Outlook

Document Preview

Page 1 of 5

Subscribe for full accessStart Free Trial